Document Type
Letter to the Editor
Publication Date
5-10-2021
Publication Title
Alzheimer's Research and Therapy
Volume
13
Issue
1
First page number:
1
Last page number:
3
Keywords
Aducanumab; Clinical trials; Donanemab; FDA; Gantenerumab; Lecanemab; Monoclonal antibodies
Disciplines
Cognitive Neuroscience
File Format
File Size
803 KB
Language
English
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Repository Citation
Cummings, J.,
Aisen, P.,
Lemere, C.,
Atri, A.,
Sabbagh, M.,
Salloway, S.
(2021).
Aducanumab Produced a Clinically Meaningful Benefit in Association With Amyloid Lowering.
Alzheimer's Research and Therapy, 13(1),
1-3.
http://dx.doi.org/10.1186/s13195-021-00838-z